Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial.
By M. Ledwidge, J. Gallagher, C. Conlon, E. Tallon, E. O’Connell, Ian Dawkins, C. Watson, R. O’Hanlon, M. Bermingham, A. Patle and 8 more. Journal of the American Medical Association (JAMA), 2013
621 citations recorded by the source corpus.
Subfields: Cardiology and Cardiovascular Medicine
View Paper: https://www.semanticscholar.org/paper/a6f255bd4338931914db5acc8d084099de217bcd
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cardiology and Cardiovascular Medicine
- G. Fonarow
- S. Anker
- Michael J. Pencina
- Gerasimos Filippatos
- J. Januzzi
- C. Yancy
- M. Drazner
- I. Neeland
Citations in the corpus
- Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association (2023, background): “Biomarker-guided strategies for disease prevention have been studied 116 and may prevent overt HF in high-risk individuals, although further studies are needed to establish clinical benefit, cost-effectiveness and optimal screening strategies for such an approach.”
- 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure (2016, positive): “Most statin trials excluded patients with HF (because it was uncertain that they would benefit).204 The two major trials that studied the effect of statin treatment in patients with chronic HF did not demonstrate any evidence of benefit.205 Therefore, evidence does not support the initiation of stat”
- 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. (2017, background): “In a large-scale unblinded single-center study (STOP-HF [The St Vincent’s Screening to Prevent Heart Failure]) (85), patients at risk of HF (identified by the presence of hypertension, diabetes mellitus, or known vascular disease [e.g., stage A HF]), but without established left ventricular systolic”
- Universal Definition and Classification of Heart Failure. (2021, methodology): “Supporting this concept was the STOP-HF trial, which provided evidence that screening with natriuretic peptides among individuals with cardiovascular disease or with cardiovascular risk factors, such as diabetes and hypertension, can be helpful to prevent development of HF or left ventricular systol”
- A Synopsis of the Evidence for the Science and Clinical Management of Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Scientific Statement From the American Heart Association (2023, methodology): “71,105 The 2022 American College of Cardiology/American Heart Association/ Heart Failure Society of America guidelines for HF management support BNP-based measurements 71 on the basis of data from STOP-HF (St. Vincent’s Screening to Prevent Heart Failure Study) 106 and PONTIAC (NT-proBNP Guided Prim”